Prophylactic vaccination strategies for adult patients with diabetes: a narrative review of safety profiles and clinical effectiveness

Clinical and Experimental Vaccine Research, Journal Year: 2025, Volume and Issue: 14

Published: Jan. 1, 2025

This narrative review analyzed roles of several prophylactic vaccinations in adult patients with diabetes, focusing on their safety profiles and clinical effectiveness. Individuals diabetes mellitus are at increased risk for infections, making vaccination a critical component healthcare. The assessed various vaccines that particularly relevant this population, i.e., pneumococcus, meningococcus, severe acute respiratory syndrome coronavirus 2, influenza, herpes zoster, human papillomavirus, dengue. It highlighted the effectiveness these preventing serious infections improving long-term health outcomes diabetic patients. Taken together, emphasized importance reducing infection-related morbidity mortality as well encouraged fostering greater adoption advocacy immunization programs among adults.

Language: Английский

Assessment Of Knowledge And Practices Of Influenza And Pneumococcal Vaccination Among Type 1 And Type 2 Diabetes Patients In Bewal International Hospital

Pakistan Journal of Health Sciences, Journal Year: 2024, Volume and Issue: unknown, P. 73 - 78

Published: July 31, 2024

Patients with diabetes have high risk of developing pneumococcal and influenza infections are advised to take immunization for prevention against the disease. Objective: To determine level awareness behaviors pneumonia among patients type 1 2 received treatment at Bewal International Hospital, Gujar Khan. Methods: This cross-sectional study was performed diabetic clinic Khan, from June 2023 August 2023. A total 200 were included in study. Socio-demographic details noted on a pre-structured questionnaire. Questions about knowledge practices vaccination particularly asked responses noted. Results: The mean age 47.0 ± 1.18 years. 193 (96.5%) had poor regarding their vaccines. An alarming 99% people did not any clue infection diabetes. Similarly, only 1.0% good these vaccinations. Conclusions: practice is drastically low population. health care providers should educate government concrete steps towards education improvement socioeconomic condition along cost-effectiveness availability vaccines every individual

Language: Английский

Potential Use of GLP-1 and GIP/GLP-1 Receptor Agonists for Respiratory Disorders: Where Are We at?

Medicina, Journal Year: 2024, Volume and Issue: 60(12), P. 2030 - 2030

Published: Dec. 9, 2024

Chronic respiratory disorders are the third leading cause of mortality globally. Consequently, there is a continuous pursuit effective therapies beyond those currently available. The therapeutic potential glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide/GLP-1 (GIP/GLP-1) receptor agonists extends regulation glycemia, including glucometabolic, cardiovascular, renal effects, rendering them viable candidates, due to their mechanisms action, for possible treatment disorders. This manuscript aims provide comprehensive evaluation evidence on direct (cellular) indirect (metabolic) actions GLP-1 GIP/GLP-1 within pulmonary systems. In addition, it examines efficacy in addressing prevalent disorders, specifically chronic obstructive disease (COPD), asthma, pneumonia, sleep apnea, hypertension, lung cancer, transplantation. Finally, seeks identify avenues further focused research this field.

Language: Английский